Brief: Jacobio Pharma Announces Breakthrough Therapy Designation From China CDE For KRAS G12C Inhibitor Glecirasib For The Treatment Of Pancreatic Cancer
07/08/2023 16:18
Aug 7 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* JACOBIO PHARMA ANNOUNCES BREAKTHROUGH THERAPY DESIGNATION
FROM
CHINA CDE FOR KRAS G12C INHIBITOR GLECIRASIB FOR THE TREATMENT
OF PANCREATIC CANCER
Source text for Eikon: ID:nPn9Y2lyxa
Further company coverage: 1167.HK
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan